Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-LAIR1 monoclonal antibody NC525

A humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against leukocyte-associated immunoglobulin-like receptor 1 (LAIR1; LAIR-1; CD305), with potential antineoplastic activity. Upon administration, anti-LAIR1 monoclonal antibody NC525 targets, binds to and inhibits LAIR1-mediated downstream survival signaling. In addition, NC525 induces Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). This inhibits survival of LAIR1-expressing acute myeloid leukemia (AML) leukemic stem cells (LSCs) and blast cells, and decreases tumor cell proliferation. LAIR1, an immune inhibitory checkpoint receptor, is overexpressed in AML LSCs and blast cells while having a minimal expression on normal, healthy hematopoietic stem cells (HSCs.). LAIR1 plays a key role in mediating survival signaling in these tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-LAIR-1 monoclonal antibody NC525
Code name:NC 525
NC-525
NC525
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search